The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory

Tuesday, April 1, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, March 31 The Immune Tolerance Institute,Inc. (ITI) today announced a collaboration with Beckman Coulter, Inc. toestablish a Center for Critical Path Immunology to investigate the role of thehuman immune system in disease. This facility, which will be managed by ITIand located initially at Beckman Coulter's Cellular Analysis Business Group inMiami, FL, will integrate state-of-the-art genomic, cellular, proteomic andbioinformatic technology platforms to elucidate immune function in patientswith a broad array of immune-related diseases. The Center will work withacademic and corporate partners to discover and develop novel, high-valuebiomarkers that more effectively guide new drug development, includingcompanion diagnostics that match patients with therapies that will providethem the greatest benefit.

"The establishment of ITI's Center for Critical Path Immunology is thefirst step in bringing to fruition our mission to transform the drug discoveryprocess to one that identifies promising therapies in their early phases ofdevelopment, and that produces drug candidates that are safer, more highlytargeted and effective in treating immune system-related diseases," said Dr.Louis A. Matis, President and Chief Executive Officer of ITI. "We areextremely pleased to be partnering in this initiative with Beckman Coulter, aworld leader in the design and development of biomedical testing systems thatspan research, clinical trials, and diagnostics."

"Advancing 'critical path' science will lead to new approaches toinvestigate the biological mechanisms of disease and to better predict theclinical efficacy and safety of emerging therapeutics. Such efforts have thepotential to enhance drug development and reverse the recent trends that haveled to higher failure rates and reduced numbers of annual new drug approvals,"said Wade E. Bolton, Ph.D., Vice President of Custom BioPharma Solutions andServices at Beckman Coulter. "Working with the ITI and their distinguishedscientific staff, we will be able to identify new solutions and make themavailable for better patient management."

ITI is advancing a new paradigm for mechanism-based clinical development,designed to better correlate clinical outcomes with underlying diseasemechanisms. The company's technologies are being deployed in high-throughputfashion to perform comprehensive cellular, molecular and immunological assayson specimens obtained from patients during clinical trials of emergingimmunotherapeutics. The mechanistic data that are generated from these assayswill be analyzed in parallel with clinical safety and efficacy data usingcutting-edge bioinformatic approaches that leverage new insights at the nexusof emerging life science and information technologies. This approach tocritical path science is designed to shorten development times, reduce bothcosts and failure rates in drug development and guide better informed patientselection for targeted therapies.

The Immune Tolerance Institute (ITI) is a 501(c)(3) non-profit corporationfounded in partnership with the University of California, San Francisco (UCSF)to fill critical unmet needs for translating fundamental scientificdiscoveries into new therapies for the broad range of diseases related to thehuman immune system, including autoimmune diseases, allergy, asthma, cancer,and cardiovascular and infectious diseases. ITI is a milestone andvalue-driven not-for-profit company uniquely positioned at the intersection ofacademia and biopharma that offers a comprehensive constellation of scientificand bio-pharmaceutical industry expertise and services to convert knowledge-based discoveries into market-accessible products for immune system relatedconditions. The Institute is led by a management team with roots in bothbiomedical research and the biotechnology industry, and a board of directorsincluding leaders in the field of translational medicine.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store